Amanda S. Mixon

Dr. Robert Wahler Jr. @BobWRx presenting during the sponsored research showcase panel. “Support from everyone @DeprescribeUS was integral to the submissions of the grants.” #USDeN2022Live w/ moderators @mixovida & #DrSandraSimmons

Dr. Amanda Mixon @mixovida and Dr. Sandra Simmons #DrSandraSimmons moderating today’s first sponsored research panel presenter: Dr. Ariel Green #DrArielGreen #USDeN2022Live

Dr. Jinjiao Wang @JasmineJinjiaoW presenting sponsored research showcase panel. #USDeN2022Live #DeprescribingGotTalent @mixovida #DrSandraSimmons

Sponsored research showcase panel with Dr. Daniela Moga @epimoga #USDeN2022Live w/ moderators @mixovida & #DrSandraSimmons

@DeprescribeUS Thanks everyone! See you at the Annual Meeting. #DeprescribingResearchChat

#DeprescribingResearchChat Please meet us in Orlando, Florida at the #USDeN2022 Annual Network Meeting on May 11th! Learn more about it here: deprescribingresearch.org/network-activi…

@MikeSteinman @josh_niznik @DeprescribeUS Less script renewals all around! #DeprescribingResearchChat

#DeprescribingResearchChat Q5: To what extent should #Research be exploring the #Economic and #Financial impact of #Deprescribing?

@DeprescribeUS A5/2: Would pharma be interested? Maybe if fewer meds mean better adherence-->and better outcomes for disease states. #DeprescribingResearchChat

@DeprescribeUS A5: #Economic and #financial impact are critical to include in outcomes. Otherwise, it may be hard to get all the relevant stakeholders on board with #deprescribing. Not saying it will be easy but needed. #DeprescribingResearchChat

@matthew_growdon @DeprescribeUS Love the ROI idea--if we #deprescribe, then less med errors/harm, ADEs. The cost of those can be estimated. #DeprescribingResearchChat

#DeprescribingResearchChat Q4: What kind of #Research is needed to help #Patients & #Clinicians #Deprescribe?

@DeprescribeUS A4: First, easy entry. We have found many #patients reluctant to join studies. @DThomasstrayer has looked at reasons why. Mostly they don't want anyone but their #clinicians to change meds, rather than recs from study team. #DeprescribingResearchChat

@DeprescribeUS A3/3: maybe our studies will even change attitudes toward future deprescribing for patients, caregivers, and clinicians alike! #DeprescribingResearchChat

#DeprescribingResearchChat Q3: What are the most important #Outcomes for #Deprescribing #Research?

@DeprescribeUS A3/2: Outcomes like medication regimen simplicity, less trips to the pharmacy, less cost, better adherence. #DeprescribingResearchChat

@DeprescribeUS A3: What matters to the patient regarding outcomes should matter to us in #research. Quality of life, geriatric syndromes, life space are just some to consider. #DeprescribingResearchChat

@MikeSteinman @matthew_growdon @cynthiaboyd16 @DeprescribeUS We also need the indication why it was started when ordering new meds! Would be great to use indications always, at beginning/middle/end of the medication's life. #DeprescribingResearchChat

#DeprescribingResearchChat Q1: What is needed to implement lessons in #Deprescribing #Research to practice?

@MikeSteinman @heniget @josh_niznik @DeprescribeUS We are trying to look at "stickiness" of deprescribing recommendations, meaning do meds creep back into the med list? #DeprescribingResearchChat

@cynthiaboyd16 @DeprescribeUS And we can draw on the research around behavior change from other studies, ie chronic disease mgmt, clinical inertia, and patient activation. #DeprescribingResearchChat

@DeprescribeUS A2 We need both. Example: Deprescribing is to a large degree about behavior change – and other research methodologies can teach us a lot about all of our behavior, which can then inform design of trials. #deprescribingresearchchat

#DeprescribingResearchChat Q2: What is the role of randomized trails versus other #research methodology?

@DeprescribeUS A2: Not so much a # research method but stakeholders especially specialists are needed to participate in deprescribing research. #DeprescribingResearchChat